597 related articles for article (PubMed ID: 17279543)
1. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
[TBL] [Abstract][Full Text] [Related]
2. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
[TBL] [Abstract][Full Text] [Related]
3. Neonatal asphyxia in rats: acute effects on cerebral kynurenine metabolism.
Ceresoli-Borroni G; Schwarcz R
Pediatr Res; 2001 Aug; 50(2):231-5. PubMed ID: 11477208
[TBL] [Abstract][Full Text] [Related]
4. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.
Amori L; Guidetti P; Pellicciari R; Kajii Y; Schwarcz R
J Neurochem; 2009 Apr; 109(2):316-25. PubMed ID: 19226371
[TBL] [Abstract][Full Text] [Related]
5. Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria.
Miu J; Ball HJ; Mellor AL; Hunt NH
Int J Parasitol; 2009 Feb; 39(3):363-70. PubMed ID: 19000912
[TBL] [Abstract][Full Text] [Related]
6. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
Grégoire L; Rassoulpour A; Guidetti P; Samadi P; Bédard PJ; Izzo E; Schwarcz R; Di Paolo T
Behav Brain Res; 2008 Jan; 186(2):161-7. PubMed ID: 17868931
[TBL] [Abstract][Full Text] [Related]
7. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression.
Laugeray A; Launay JM; Callebert J; Surget A; Belzung C; Barone PR
Behav Brain Res; 2010 Jun; 210(1):84-91. PubMed ID: 20153778
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
[TBL] [Abstract][Full Text] [Related]
9. Perinatal kynurenine pathway metabolism in the normal and asphyctic rat brain.
Ceresoli-Borroni G; Schwarcz R
Amino Acids; 2000; 19(1):311-23. PubMed ID: 11026502
[TBL] [Abstract][Full Text] [Related]
10. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
Schwarcz R; Pellicciari R
J Pharmacol Exp Ther; 2002 Oct; 303(1):1-10. PubMed ID: 12235226
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of [5-(3)H]kynurenine in the developing rat brain in vivo: effect of intrastriatal ibotenate injections.
Ceresoli G; Guidetti P; Schwarcz R
Brain Res Dev Brain Res; 1997 May; 100(1):73-81. PubMed ID: 9174248
[TBL] [Abstract][Full Text] [Related]
12. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
Guidetti P; Bates GP; Graham RK; Hayden MR; Leavitt BR; MacDonald ME; Slow EJ; Wheeler VC; Woodman B; Schwarcz R
Neurobiol Dis; 2006 Jul; 23(1):190-7. PubMed ID: 16697652
[TBL] [Abstract][Full Text] [Related]
13. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
14. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
[TBL] [Abstract][Full Text] [Related]
15. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase.
Chiarugi A; Moroni F
Neuropharmacology; 1999 Aug; 38(8):1225-33. PubMed ID: 10462134
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Prenatal Kynurenine Metabolism Using Tissue Slices: Focus on the Neosynthesis of Kynurenic Acid in Mice.
Notarangelo FM; Beggiato S; Schwarcz R
Dev Neurosci; 2019; 41(1-2):102-111. PubMed ID: 31117076
[TBL] [Abstract][Full Text] [Related]
17. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
Guidetti P; Luthi-Carter RE; Augood SJ; Schwarcz R
Neurobiol Dis; 2004 Dec; 17(3):455-61. PubMed ID: 15571981
[TBL] [Abstract][Full Text] [Related]
18. In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum.
Guidetti P; Wu HQ; Schwarcz R
Exp Neurol; 2000 May; 163(1):123-30. PubMed ID: 10785450
[TBL] [Abstract][Full Text] [Related]
19. Drosophila eye color mutants as therapeutic tools for Huntington disease.
Green EW; Campesan S; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
Fly (Austin); 2012; 6(2):117-20. PubMed ID: 22634544
[TBL] [Abstract][Full Text] [Related]
20. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
